RxTrials Institute Drug Pipeline Alert

Avicena Group will proceed with a Phase III trial of HD-02 for the treatment of Huntington’s disease pending final analysis of completed animal toxicology studies.

A double-blind, placebo-controlled trial will evaluate the ability of HD-02 to slow functional decline in Huntington’s disease patients. Enrollment is anticipated to begin in the third quarter, Avicena said.

The FDA awarded orphan drug designation to the candidate in 2006.